ESALF News and Press, Eisai Co Ltd From 02/13/24

2024-02-13 07:59:24 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen misses top-line and bottom-line estimates; initiates FY...

2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...

2024-02-06 20:49:04 ET Eisai Co Ltd (ESALF) Q3 2023 Results Conference Call February 06, 2024 01:00 AM ET Company Participants Mitsuru Shomon - CFO Keisuke Naito - Global AD Officer Lynn Kramer - Chief Clinical Officer Takashi Owa - Chief Scientific Officer ...

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd ("Eisai South Africa"), a pharmaceuti...

2024-01-30 16:23:19 ET Summary Anti-amyloid drugs likely have little effect on non-APOE4 carriers. Anti-amyloid antibody drugs may have an effect on APOE4 carriers, but with serious and potentially fatal side effects. Safety issues, including potential adverse brain events, ma...

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mec...

2024-01-24 08:54:54 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai...

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulati...

Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time TOKYO, Jan 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-bas...

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and ...